With the announcement of October's revenue, there is a chance that the monthly revenue will reach NT$900 million, a huge jump from the previous month and the same period last year, and the annual revenue will exceed NT$9.5 billion. TaiDoc has successfully entered the antigen fast track market in the past three years. In the past three years, TaiDoc has successfully entered the antigen fast screening market and achieved a leading position in Taiwan.

The global economy is full of uncertainties, and companies with high EPS and high dividend payout have become the focus of market attention. In anticipation of the strong trend of the US dollar in the short term, half of the cash has been transferred to US dollar fixed deposits, which will make a good contribution to profitability as a result of high interest rates.

The fourth quarter is the traditional peak season for the medical industry, and TaiDoc's existing products such as blood glucose are in steady shipment. Full-year revenue will exceed $9.5 billion, and we do not rule out the possibility of approaching the $10 billion mark, setting a new record again.